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ANALISIS ANTIGEN REMBESAN PERKUMUHAN Toxoplasma gondii DAN 
MENGENALPASTI PENANDA POTENSI INFEKSI AKUT 
 
ABSTRAK 
 
Toxoplasma gondii merupakan parasit protozoa obligat intrasellular. Infeksi oleh 
organisma ini tersebar luas dan penting kepada manusia, khususnya wanita hamil dan 
pesakit yang sistem imunnya terkompromi.  Melainkan jika dirawat, toksoplasmosis 
boleh menyebabkan morbiditi yang teruk bahkan kematian. Dengan itu ujian makmal 
yang sesuai adalah sangat penting untuk mengenalpasti kes toksoplasmosis akut atau 
teraktif semula. Diagnosis toksoplasmosis akut masih mempunyai banyak cabaran, di 
mana satu panel ujian diperlukan untuk pengesahan penyakit ini. Antigen rembesan 
perkumuhan (ESA) toksoplasma sangat imunogenik dalam infeksi, baik pada 
manusia mahu pun infeksi eksperimental. Sehubungan dengan itu,  ESA merupakan  
antigen yang sesuai untuk penyelidikan penanda infeksi baru, terutama untuk 
mengesan kes toksoplasmosis akut. Dalam kajian ini, ESA dihasilkan melalui dua 
pendekatan iaitu: 1) daripada takizoit T.gondii strain RH melalui infeksi 
intraperitoneum pada mencit Swiss albino, 2) daripada kultur in vitro T.gondii. 
Dalam penghasilan ESA in vitro, optimisasi  kaedah kultur sel untuk propagasi T. 
gondii dilakukan untuk mendapatkan sumber parasit yang konsisten dengan hasil dan 
viabiliti yang maksimum, disamping pencemaran sel perumah yang minimum. 
Sampel serum diperolehi daripada pelbagai kategori individu : pesakit yang disyaki 
terjangkit dan positif untuk antibodi anti- Toxoplasma IgM dan negatif / positif untuk 
anti- Toxoplasma IgG; individu yang mengidap jangkitan kronik dan positif untuk 
anti- Toxoplasma IgG tetapi negatif untuk anti- Toxoplasma IgM, dan daripada 
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pesakit yang mengidap jangkitan lain, serta daripada individu sihat sebagai kumpulan 
kawalan. Analisis SDS-PAGE dijalankan ke atas ESA, diikuti dengan analisis 
Western blot menggunakan serum di atas dan di prob dengan antibodi anti-manusia 
IgM dan IgA yang terkonjugat dengan enzim peroxidase (HRP). Substrat 
kemiluminesen digunakan untuk mengesan reaktivi Western blot. Jalur antigenik 
dengan anggaran berat molekul 30, 20, dan 12 kDa daripada ESA in vivo dan 10 kDa 
daripada ESA in vitro menunjukkan potensi yang baik sebagai penanda infeksi akut. 
Sensitiviti maksimum bagi jalur daripada ESA in vivo adalah 98.7% dengan 
kombinasi blot IgM dan IgA, manakala  spesifisiti adalah 84% dan 70% apabila  di 
uji dengan serum daripada jangkitan lain dan individu sihat, masing-masing untuk 
blot IgM dan IgA. Manakala untuk ESA in vitro, sensitiviti adalah  80% dan 
spesifisitinya adalah 96.7% dengan kombinasi blot IgM dan IgA. Elektroforesis gel 
dua dimensi dilakukan melalui kaedah fraksinasi OFF GEL untuk menentukan titik 
isoelektrik protein, diikuti dengan analisis SDS-PAGE. Hal ini membolehkan jalur 
protein dipisahkan dengan baik untuk dipotong dan dikenal pasti dengan mass 
spektrometri (analisis MALDI TOF /TOF). Dua daripada tiga protein yang telah 
dikenal pasti pada setiap penanda infeksi tersebut adalah seperti berikut; ubiquitin 
(protein ribosomal CEP52 protein cantuman) dan polyubiquitin untuk protein bersaiz 
10 kDa; protein microneme 10 dan protein dense granul 7 untuk protein bersaiz 20 
kDa; dan phosphoglycerate mutase 1 dan phosphoglycerate mutase untuk protein 
bersaiz 30 kDa.  Bagi protein 12 kDa, ia dikenalpasti sebagai thioredoxin. Kajian ini 
telah beraya mengenalpasti komponen ESA dengan nilai diagnostik yang berpotensi 
untuk mengesan antibodi anti-Toxoplasma IgA dan IgM dalam infeksi 
toksoplasmosis akut. 
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ANALYSIS OF Toxoplasma gondii EXCRETORY SECRETORY ANTIGENS (ESA) 
AND IDENTIFICATION OF POTENTIAL MARKERS OF ACUTE INFECTION 
 
ABSTRACT 
 
Toxoplasma gondii is an obligate intracellular protozoan parasite. Infection with this 
organism is widespread and important in humans, especially pregnant women and 
immunosuppressed patients. Unless treated, it can result in severe morbidity and 
even death. These severe sequelae thus emphasize the importance of appropriate 
laboratory investigations in potential cases of acute/reactivated Toxoplasma 
infection. Diagnosis of acute toxoplasmosis still poses a lot of challenges, and a 
panel of tests is required for confirmation of toxoplasmosis. Excretory secretory 
antigens (ESA) are highly immunogenic during both human and experimental 
infections. Thus they are good candidates for investigation into new infection 
markers, especially for detection of probable cases of acute toxoplasmosis. In this 
study, ESA was prepared using two approaches namely: 1) from tachyzoites of RH 
strain of T. gondii by intraperitoneal infection of Swiss albino mice, 2) from in vitro 
culture of T. gondii.  For use in production of the in vitro ESA, optimizations of cell 
culture method for T. gondii propagation was performed to obtain a consistent source 
of parasites with maximum yield and viability, but minimum host cell contamination. 
Serum samples were obtained from various categories of individuals: probable cases 
of acute toxoplasmosis from patients suspected of toxoplasmosis who were positive 
for anti-Toxoplasma IgM and negative/positive for IgG; chronically infected patients 
who were positive for anti-Toxoplasma IgG but negative for IgM; and from patients 
with other infections, as well as from healthy controls. The ESA was subjected to 
SDS-PAGE, followed by Western blot analysis using the above sera and probed with 
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peroxidase conjugated anti-human IgM and IgA antibodies. The blots were then 
developed using chemiluminescence substrate. Antigenic bands of approximate 
molecular weights of 30, 20, and 12 kDa from in vivo ESA and 10 kDa from in vitro 
ESA when probed with anti-human IgM-HRP and IgA-HRP showed good potential 
as acute infection markers. The maximum sensitivity of bands from in vivo ESA was 
98.7% with combination of IgM and IgA blots; while the specificities were 84% and 
70% when probed with serum from other infections and healthy controls in IgM blots 
and IgA blots respectively. Meanwhile for in vitro ESA, 80% sensitivity and 96.7% 
specificity were obtained with combination of IgM and IgA blots. Two-dimensional 
gel electrophoresis was performed by OFF GEL fractionation to determine the 
isoelectric points of the proteins, followed by SDS-PAGE analysis. This enabled the 
well-separated bands to be excised for identification by mass spectrometry (MALDI 
TOF/TOF analysis). The two top identifications for three of the proteins were as 
follows; ubiquitin (ribosomal protein CEP52 fusion protein) and polyubiquitin for 10 
kDa; microneme protein 10 and dense granule protein 7 for 20 kDa; and 
phosphoglycerate mutase 1 and phosphoglycerate mutase for 30 kDa protein. The 
protein indentified for 12 kDa was thioredoxin. In this study ESA components with 
potential diagnostic value for detection of anti- Toxoplasma IgA and IgM during the 
acute toxoplasmosis were successfully identified.  
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Overview of toxoplasmosis 
Toxoplasmosis, caused by intracellular protozoan parasite, Toxoplasma gondii, is 
widely spread throughout the world (Jackson & Hutchison, 1989). In recent years, 
the significance of congenital toxoplasmosis has been increasingly recognized 
(Bhopale, 2003a) and it is documented that over half a billion of the world’s human 
population has serum antibodies to T. gondii (Dubey, 1997). The incidence of 
toxoplasmosis, especially toxoplasmic encephalitis, has risen dramatically within the 
increasing population of patients with AIDS (Luft & Remington, 1992), whereas 
patients with a variety of neoplastic diseases as well as patients receiving 
immunosuppressive therapy are at risk of reactivation of T. gondii infection (Israelski 
& Remington, 1993).  
 
The term ‘toxoplasmosis’ describes the clinical or pathological disease caused by 
Toxoplasma gondii i.e. symptomatic course of infection. T. gondii infection is 
reserved to describe the asymptomatic primary infection or persistence of the parasite 
in tissues (chronic or latent infection) observed in the majority of infected 
immunocompetent individuals (Remington et al., 2001). In clinical aspects, 
toxoplasmosis can be divided into five categories, namely those (1) acquired by 
immunocompetent patients, (2) acquired during pregnancy, (3) acquired 
congenitally, (4) acquired by or reactivated in immunodeficient patients, and (5) 
ocular infections. In any of the above categories, clinical presentations are not.           
. 
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specific and a wide differential diagnosis must be considered since methods of 
diagnosis and their interpretations may vary for each clinical category (Montoya, 
2002). In view of the above facts, it emphasizes the importance of understanding the 
overall aspects of toxoplasmosis and T. gondii infection for a better prevention, 
diagnosis and treatment of the disease. 
 
1.2 Historical perspective of Toxoplasma gondii 
T. gondii protozoan parasite was first discovered in 1908 by Nicolle and Manceaux 
(1908 cited in Louis & Kami, 2007) and named a year later based on its morphology. 
The name Toxoplasma was derived from Greek word “toxo,” meaning arc or bow, 
which resembled the curved shape of the trophozoites and “plasma,” referring to life 
(Nicolle & Manceaux, 1909 cited in Louis & Kami, 2007). Its medical importance 
remained unknown until 1939 when T. gondii was identified in tissues of a 
congenitally infected infant (Wolf et al., 1939). Veterinary importance became 
known when epidemic toxoplasmosis abortions were recognized in sheep (Hartley & 
Marshall, 1957). The discovery of a T. gondii specific antibody test, the Sabin 
Feldman dye test, in 1948 led to the recognition that T. gondii is a common parasite 
of warm-blooded hosts with a worldwide distribution (Sabin & Feldman, 1948). 
Frenkel et al. discovered T. gondii life cycle in 1970 when they found that felids are 
its definitive host and an environmentally resistant stage (oocyst) is excreted in feces 
of infected cats (Frenkel et al., 1970). The discovery of its widespread infection in 
certain marine wildlife (sea otters) indicates contamination of our seas with T. gondii 
oocysts washed from land (Cole et al., 2000). Since there is still no vaccine to 
prevent toxoplasmosis in humans, hygiene remains the best preventive measure 
(Dubey, 2008). 
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1.3 Epidemiology of Toxoplasma infection 
Toxoplasmosis is a zoonosis distributed worldwide. In humans, the prevalence of the 
infection rises with age, and does not vary greatly between sexes. Toxoplasma 
infection shows different incidence in different climate, with lower incidence in cold 
regions, hot and arid areas, or at high elevations (Montoya & Liesenfeld, 2004). In 
general, there are considerable geographic differences in toxoplasmosis prevalence 
rates (Figure 1.1). For instance 10% in Palo Alto, California; 15% in Boston, 
Massachusetts; 30% in Birmingham, Alabama; 36% in Strasbourg, France; 81% in 
the Central African Republic (Remington et al., 2001). The difference of the 
incidence of toxoplasmosis infection with the population group within the same 
environment may be explained by differences in exposure to sources of the infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.1 Distribution of human toxoplasmosis (Tenter et al., 2000) 
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In a National Health and Examination Survey in the USA from 1999- 2000, 4234 
sera samples were collected from persons aged 12 to 49. Based on this survey 84.2% 
of women of childbearing age in the United States were found to be seronegative, 
and thereby are at risk of acquiring T. gondii infection during gestation. T. gondii 
antibody prevalence was higher among non-Hispanic black persons than among non-
Hispanic white persons, and increases with age (Jones, et al., 2003). Lopez et al., in 
the year 2000 studied the rate of congenital toxoplasmosis in the United States, and 
estimated that between 1- 10 per 10,000 live births and 400 to 4000 infants would be 
born each year with congenital toxoplasmosis. 
 
There are three factors that directly correlate with the incidence of congenital 
toxoplasmosis in newborns, namely (1) the incidence of primary infection among 
women during pregnancy; (2) the gestational age at which a pregnant woman 
acquires the infection; and (3) the public health programs instituted for prevention, 
detection, and treatment of the infection during pregnancy. Even though in some 
countries the screening for Toxoplasma infection is compulsory during pregnancy 
such as Austria and France, in many countries routine serological screening is still 
not performed (Montoya & Rosso, 2005). 
 
T. gondii seroprevalence in women at child-bearing age was reported by Tenter et 
al., (2000), nation-wide data collection. The rates of positive seroprevalence were 
58% in Central European countries, 51–72% in several Latin-American countries, 
and 54–77% in West African countries. Low seroprevalence, 4–39%, was reported in 
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southwest Asia, China and Korea as well as in cold climate areas such as 
Scandinavian countries (11–28%) (Tenter et al., 2000). 
 
In Malaysia the seroprevalence of toxoplasmosis have been reported in several 
studies.  Nissapatorn and Khairul, (2004) reported that the seroprevalence of 
toxoplasmosis among 505 HIV/AIDS patients who were admitted at the Hospital 
Kuala Lumpur during January 2001- December 2002 was 226 (44.8 %). This 
seroprevalence was much higher than in other similar studies, e.g. 15-37% in France 
(Leport & Remington, 1992), 21% in Malaysia (Nissapatorn et al., 2002), 22.4% in 
Thailand (Nissapatorn et al., 2001) and 10-40% in USA (Luft & Remington, 1988). 
The majority of patients were male (75.7%), Chinese (53%), married (51.3%), 
unemployed (51.3%,) and heterosexual who engaged commercial sex workers 
(59.3%) who are at risk of HIV infection (Nissapatorn et al., 2004). The 
seroprevalence of toxoplasmosis in Malaysian pregnant women was found to be 49% 
(Azmi et al., 2003). In one study, congenital toxoplasmosis (IgM positive), was 
found only in 12 (0.35%) of 3420 infants whom were clinically suspected of 
acquiring congenital infection (Osman et al., 1992). It was also reported that there 
was a significant difference (p<0.05) in Toxoplasma seroprevalence rates among 
races; the highest rate was in the Malays (55.7%), followed by the Indian (55.3%) 
and the Chinese (19.4%) (Azmi et al., 2003).  
 
 
 
 
 
7 
 
1.4 Toxoplasma gondii and its life cycle 
The life cycle of T. gondii is illustrated in Figure1.2. T. gondii is an obligate 
intracellular protozoan that exists in nature in three forms namely oocyst, tissue cyst 
and tachyzoites. The oocyst (Figure 1.3.a) releases sporozoites and can spread in the 
environment and contaminate water, soil, fruits, vegetables and herbivores following 
consumption of infected plant material (Coutinho et al., 1982). Oocytes have been 
found to be very stable, particularly in warm and humid environments, and resistant 
to many disinfecting agents (Dumetre & Darde, 2003), but survive poorly in arid, 
cold climates (Jones et al., 2001). The tissue cyst (Figure 1.3.b) harbours 
bradyzoites, is the encysted stage which contains relatively slowly multiplying 
organisms (brady=slow, zoite=organism). Bradyzoites are also called cystozoites. 
Tissue cysts persist in the body as long as the host lives (Frenkel, 1973a). 
Tachyzoites (tachy=fast, Figure 1.3.c) has also been called a trophozoite, the 
proliferative form, the feeding form, and the endozoite. It divides into two by a 
specialized process called endodyogeny (Goldman et al., 1958).   
 
 
 
 
 
 
 
 
 Figure 1.2 Pathways for Toxoplasma gondii infection 
The feline intestinal tract is the only source for the production of T. gondii 
oocysts. Transmission to humans usually occurs through the ingestion of 
oocysts from contaminated sources (e.g., soil, cat litter, garden vegetables, 
and water) or the ingestion of tissue cysts in undercooked meat from infected 
animals. Although fetal infection most often occurs after acute T. gondii 
infection in a pregnant woman, it also can occur after the reactivation of 
latent infection in an immunocompromised pregnant woman (Jones, et al., 
2003). 
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Figure1.3.a. T. gondii oocysts in a fecal floatation 
www.dpd.cdc.gov/.../body_Toxoplasmosis_il6.htm 
 
 
 
 
Figure 1.3.b. T. gondii cyst in brain tissue stained with hematoxylin and eosin 
www.dpd.cdc.gov/DPDx/HTML/.../body_Toxoplasmosis_mic1.htm 
 
 
 
 
Figure 1.3.c. T. gondii tachyzoites, stained with Giemsa, from a smear of peritoneal 
fluid obtained from a laboratory-inoculated mouse (author) 
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Tachyzoite is crescent or oval-shaped (approximately 2 by 7 μm) (Figure 1.4), 
comprised of a unique cytoskeleton (subpellicular microtubules, conoid), 
endosymbiontic derived organelles (mitochondrion, apicoplast) and secretory 
organelles (rhoptries, micronemes, dense granules) other than the eukaryotic 
universal organelles. The conoid is a concave truncated cone consisting of fibers 
wound into a spiral, like a compressed spring. It is made of tubulin organized in a 
unique fashion, very different from typical microtubules (Hu et al., 2002). Apicoplast 
is a typical plastid placed above the Golgi, limited by multiple membranes. In the 
infectious stage it is relatively uniform in shape, bounded by possibly four 
membranes, and filled with granular and filamentous content (Kohler, et al., 1997).  
 
There are three dissimilar secretory organelles that are essential for T. gondii 
invasion. First are micronemes which are small and rod-shaped structures, located in 
the most apical area of the parasite, behind the conoid. Second are the rhoptries, 
organized as a group of elongated, club-shaped organelles that extend from within 
the conoid toward the nucleus. The third type are dense granules, with spherical-
shaped, found throughout the cell but mostly in the posterior part of the parasite. 
With the advantages of antibody development to specific proteins, it has been 
possible to begin to identify proteins specifically located in the different organelles 
(Louis & Kami, 2007).  
 
 
 
 
 
  
 
 
 
 
Figure 1.4 Schematic representation of T. gondii tachyzoite 
http://journals.cambridge.org/fulltext_content/ERM/ERM3_01/S1462399401002204
sup002.htm 
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Tachyzoites require an intracellular habitat to survive and multiply, they reside and 
multiply within vacuoles in their host’s cells, and can infect most phagocytic and 
nonphagocytic cell types, including placental cells. The presence of tachyzoites in 
human fluids or tissues is the hallmark of acute infection or reactivation of a latent 
infection (Singh, 2003). Ultrastructural studies revealed that tissue cysts develop and 
remain intracellular and bradyzoites differ from tachyzoites with respect to location 
of the nucleus that is central in tachyzoites and terminal in bradyzoites; amylopectin 
granule that is numerous in bradyzoites but absent or few in tachyzoites, and contents 
of rhoptries which is honeycomb in tachyzoites, but electron dense in older 
bradyzoites (Wanko et al., 1962; Ferguson & Hutchison, 1987; Dubey et al., 1998). 
 
The life cycle of T. gondii consists of sexual and asexual stage that is divided 
between feline and non-feline infections, respectively (Figure1.2). The sexual stage 
takes place in the intestine of the definitive host, predominantly domestic cats which 
belong to the feline family. When bradyzoites or oocytes are ingested by a feline, 
formation of oocytes proceeds in the epithelium of the small intestine. Several 
million unsporulated oocytes may be released in the feces of a single cat over a 
period of 3–18 days, depending on the stage of the parasite ingested (Dubey et al., 
1998). In mild environmental conditions, oocytes may sporulate within a 3-week 
period (Dubey et al., 1970), then infect humans and other intermediate hosts. Thus 
far the  investigation of outbreaks of toxoplasmosis has led to recovery of oocytes 
from soil (Coutinho et al., 1982) but not from water (Benenson et al., 1982; Bowie et 
al., 1997; Bahia-Oliveira et al., 2003).  
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The asexual cycle consists of two distinct stages of growth depending on whether the 
infection is in the acute or chronic phase. The tachyzoite stage defines the rapidly 
growing form of the parasite found during the acute phase of toxoplasmosis. 
Tachyzoites are approximately 5 mm long and 2 mm wide (Smith, 1995). Usually 
after 64 to 128 parasites have accumulated per cell they undergo replication with a 
generation time of 6 to 8 hours (in vitro) until they exit the cell to infect 
neighbouring cells (Radke & White, 1998). In infected animals, tachyzoites 
differentiate into bradyzoites and form tissue cysts that first appear 7 to 10 days post-
infection. These cysts are found predominantly in the central nervous system and 
muscle tissue, where they may reside as long as the host lives. The chronic stage of 
the asexual cycle occurs when there is a development of tissue cysts throughout the 
body. As they pass through the digestive tract, cysts that are ingested through eating 
infected tissue are ruptured, therefore causing bradyzoite release. These bradyzoites 
can then infect the epithelium of the intestinal lumen, and finally complete the 
asexual cycle by differentiating back to the rapidly dividing tachyzoite stage for 
dissemination throughout the body (Black & Boothroyd, 2000).  
 
Under some conditions within the host, there is apparently a low rate of spontaneous 
reactivation whereby bradyzoites differentiate back to tachyzoites. In general, the 
immune response can efficiently prevent the dissemination of these tachyzoites but in 
immunocompromised hosts, however, such reactivation may be unchecked and/or 
become more frequent. This leads to the suggestion that the parasites might actively 
detect a lowered immunity against them (Gross & Pohl, 1996). In either case, the 
consequence can be a massive and potentially fatal recrudescence (Black et al., 
2000) 
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The transmission and sources of human infection are further elaborated in section 
1.9.  
 
 
1.5 Immunology of Toxoplasma infection 
 T. gondii stimulates the production of IgG, IgM, IgA and IgE antibodies against both 
membrane and excretory secretory antigens (Schreiber & Feldman, 1980). 
Additionally IgA antibody may interfere with the initial interaction of the parasite 
with the host cell at mucus membrane. Human platelets are cytotoxic to tachyzoites 
in the absence of antibody (Yong et al., 1991). In a normal immune host, both 
cellular and the humoral immune responses control the infection, and it depends on 
the strain of T. gondii. Macrophages are not the only effector cells but are closely 
involved in regulation of cellular immunity through their production of 
immunological mediators. Tachyzoites stimulate macrophages to produce interleukin 
(IL-12) (Gazzinelli, et al., 1993; Sher & Reis, 1998). IL-12, in turn activates natural 
killer (NK) cells and T cells to produce interferon- γ (IFN- γ). Production of IFN- γ is 
crucial for resistance to the infection (Gazzinelli et al., 1994; Daubener et al., 1996). 
The synergistic act of IFN-γ and tumour necrosis factor (TNF) results in greatly 
enhanced production of free radicals and nitric oxide, both of which can mediate 
killing of tachyzoites by macrophages (Sibley et al., 1991; Langermans et al., 1992; 
Sher et al., 1993). 
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CD8+ T cells are considered to be the major effector cells among the T cell 
population. They are responsible for protection against T. gondii with CD4+ T cells 
playing a synergistic role (Parker et al., 1991; Denkers et al., 1996). T helper (Th-1) 
CD4+ T cells produce IL-2 (Khan et al., 1994). IL-2 induces lymphokine activated 
killer cells at either NK cells or T cell phenotype which are cytotoxic for target cells 
infected with T. gondii. T helper cells (Th-2) are responsible for down regulation of 
protective cell mediated immune response cells by producing IL-4, IL-5 and IL-10 
(Mosmann & Moore, 1991). In brain which is the most commonly affected site of 
latent Toxoplasma infection, CD4+ and CD8+ cells were reported to infiltrate into 
the CNS of mice (Hunter, et al., 1994). T cell encounters parasite antigen that are 
likely presented by Glial cells in the context of major histocompatibility complex. 
This may result in production of cytokines such as INF- γ which can activate 
microglia to inhibit parasite replication and induction of cytotoxic T cells to lyse 
infected cells (Hunter & Remington, 1994).  
  
1.6 Pathogenesis 
Humans are generally infected by T. gondii through ingestion of oocysts released in 
cat feces or by consuming uncooked/ undercooked meat from infected flock animals 
containing the long lived tissue cysts (Jackson & Hutchison, 1989). The ingestion of 
oocyst is an important source of infection. After ingestion, the outer walls of cysts or 
oocysts are ruptured by enzymatic degradation and bradyzoites and sporozoites are 
released into the intestinal lumen. Subsequently they invade and multiply within their 
surrounding cells and become tachyzoites inside the cells. Following that, the 
tachyzoites circulate via blood or lymphatic system to most of the organs of human.    
. 
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 body (Frenkel, 1971). Thus, the host cells would be infected by the tachyzoites, 
replicate and invade the adjoining cell. In this phase, the acute features of the 
infection develop i.e. cell death and focal necrosis surrounded by an acute 
inflammatory response (Bhopale, 2003b). 
 
T. gondii is able to invade any nucleated cell, the preliminary step of the parasite 
invasion process is recognition and attachment to the target cell. Upon encountering 
the host cell, the parasite attach to the cell membrane in an appropriate point that is 
recognized by the apical pole (Kasper & Mineo, 1994). Rhoptries and micronemes 
are two types of the organelles that appear to be involved at the anterior end of the 
parasite. ROP1, a rhoptry protein is secreted at the time of invasion and is associated 
with membrane of parasitophorous vacuoles (Kasper & Mineo, 1994). Two 
microneme proteins MIC-1 and MIC-2 contain thrombspondin like domains that may 
function in adhesion following their release on the surface of the parasite (Fourmaux 
et al., 1996; Wan et al., 1997). 
 
An annular junction is formed between parasite and host cell membrane once the 
parasite attaches to its target cell, through which the parasite forcibly penetrates the 
host cell while apparently pulling the cell membrane around itself. Finally, the 
parasite is enclosed within a parasitophorous vacuole. Extracellular tachyzoites are 
highly susceptible to oxygen intermediates, changes in pH and osmotic variation and 
are killed by specific antibody in the presence of complement (Bhopale, 2003a and 
2003b). The formation of tissue cysts under certain circumstances is an important        
. 
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aspect of the pathogenesis of toxoplasmosis. It has been observed that inhibitors of 
mitochondrial function promote the transformation of tachyzoites to bradyzoites 
suggesting that the reliance of the parasite on mitochondrial function might be 
different in tachyzoites and bradyzoites (Bohne et al., 1994; Tomavo & Boothroyd, 
1995).  
 
In general, pathogenesis of T. gondii infection can be divided into three different 
phases: first, the acute phase when tachyzoites multiply actively, disseminating 
through the lymphatic system to the different organs, and undergo intracellular 
growth causing cell necrosis. During this time parasites can be excreted through 
different biological fluids (faeces, urine, etc.), but these tachyzoites are very unstable 
and are easily destroyed (Montoya & Liesenfeld, 2004). Second is sub-acute phase 
that is characterized by the appearance of IgA antibodies specific for T. gondii 
enteroepithelial stages, which eliminate tachyzoite replication in the intestinal phase 
but not those localized in the nervous system. Third is the chronic phase that starts 
with tachyzoites beginning to disappear from visceral tissues and is characterized by 
persistence of bradyzoites within cysts. This phase is associated with a systemic 
immune response, which inhibits tachyzoites proliferation in blood and tissues such 
as liver, spleen, lungs, etc (Montoya & Liesenfeld, 2004).  
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1.7 Clinical Disease  
Toxoplasma gondii infection is one of the most common human zoonosis. 
Toxoplasmosis is a systemic disease, clinically, infection with T. gondii can go 
unnoticed or could cause signs and symptoms depending on the immune status of the 
patient and the clinical setting e.g. immunocompetent, immunocompromised, 
congenital toxoplasmosis or ocular disease (Biesiada et al., 2006). 
 
1.7.1 Infection in immunocompetent individuals 
Acute acquired infection with T. gondii in immunocompetent individuals most often 
is asymptomatic. Sign and symptom of infection present only in minority of 
individuals that are acutely infected with T. gondii (Remington, 1974). T. gondii 
infection usually causes self limiting and unspecific illness, therefore no treatment is 
needed. The most common clinical presentation is cervical lymphadenopathy that is 
present in 5% of clinically significant lymphadenopathy cases (McCabe et al., 1987). 
Fever, headache, sore throat, cough, myalgia, malaise and night sweats are some of 
the general symptoms of toxoplasmosis in immunocompetent individuals. Rarely, 
myocarditis, polymyositis, pneumonitis, hepatitis and encephalitis can arise in 
healthy individuals (Montoya & Liesenfeld, 2004). Acute T. gondii infection in 
pregnant women is similar to T. gondii infection in other immunocompetent 
individuals. Most commonly the infection manifest as asymptomatic diseases, 
although cervical lymphadenopathy may occur. Acute infection may be transmitted 
to the fetus but, since it is asymptomatic, the infection often goes unnoticed (Louis & 
Kami, 2007). 
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1.7.2 Infection in immunocompromised patients 
Toxoplasma gondii is one of the most frequent protozoan causing opportunistic 
infections in immunocompromised individuals. Host immune function plays an 
important role in the pathogenicity of toxoplasmosis (Ferreira & Borges, 2002). 
Patients who are immunocompromised often develop life-threatening toxoplasmosis 
(Liesenfeld et al., 1999).  
 
Toxoplasmosis occurs as a consequence of reactivation of a latent infection in 
patients infected with AIDS (Luft et al., 1992). It is believed that in patients with 
AIDS, the most common non-viral infection of the brain is toxoplasmosis. In HIV-
infected patients, ocular toxoplasmosis can occur before the development of AIDS 
(Cristina & Rubens, 2007). Encephalitis is the clinically important manifestation of 
toxoplasmosis in AIDS patients and it is one of the most common cause of death 
among these patients (Dubey, 2004). However the risk of toxoplasmosis has 
decreased after introduction of primary prophylaxis against T. gondii and effective 
antiretroviral therapy (Jones et al., 1999). 
 
The clinical presentation of toxoplasmosis in immunocompromised patients ranges 
from asymptomatic reactivation, commonly observed in previously infected organ 
recipients and demonstrable by increased post-transplant antibody titers, to severe 
disseminated disease (Ferreira et al., 2002). Toxoplasmosis encephalitis has always 
been recognized as the most common opportunistic infection of the central nervous 
system (CNS). Clinical appearance of toxoplasmic encephalitis varies from a 
subacute gradual process evolving over weeks, to an acute confusional state, with or 
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without focal neurological deficit, evolving over days (Yeo et al., 1983). Clinical 
manifestations include mental status changes, seizures, focal motor deficits, cranial 
nerve disturbances, sensory abnormalities, cerebellar signs, movement disorders and 
neuropsychiatric findings. Meningeal signs are rare. Constitutional symptoms and 
signs such as fever and malaise can vary. The most typical focal neurological 
findings are hemiparesis and speech abnormalities (Luft et al., 1993). Toxoplasma 
pneumonia seems to be more frequent in recipients of bone-marrow transplants and 
 in patients with AIDS (Montoya & Liesenfeld, 2004). Elderly patients who acquire 
toxoplasmosis are at risk of developing a severe retinochoroiditis, likely secondary to 
the weakening of cellular immune function that occurs with aging (Lihteh, 2007).  
 
Individuals under immunosuppressive therapy such as patients with malignant 
diseases or organ transplant recipients, who had been previously infected with T. 
gondii, might show an altered serological profile of this protozoan compatible with 
reactivation, such as increased IgG antibody titers or, less frequently, increased titers 
of acute phase antibodies, i.e. IgM, 4 to 13 weeks after the beginning of 
immunosuppression, and the presence or absence of clinical manifestations, a fact 
not observed in patients with AIDS. Alternatively, seronegative patients receiving 
organs from seropositive donors may show seroconversion 4 to 6 weeks after 
transplantation, in general accompanied by disseminated infection whose clinical 
manifestation usually happen at the same time with the occurrence of antibodies, 
although late manifestations, (about 10 months) after immunosuppressive therapy, 
have been reported (Luft et al., 1983).  
 
